News

Oncoinvent awarded 4,6 MNOK in Innovation Funding

Press Release 04.2019: Oncoinvent is pleased to announce that the Oslo University Hospital and Oncoinvent have each been awarded Innovation Funding to develop Radspherin® as a treatment for colorectal cancer patients suffering from peritoneal carcinomatosis. The two awards make for a combined total of 7,9 million NOK where Oncoinvent will receive 4,6 MNOK and Oslo University Hospital 3,3 MNOK. The Innovation Norway grants will allow Oncoinvent to expand the clinical use of Radspherin® from the current planned study in ovarian cancer patients and enables the company to carry out phase 1 clinical trials to assess the clinical safety of Radspherin® in colorectal cancer patients as well.

Read More »

Oncoinvent announces appointment of new Chief Financial Officer

Press Release 02.2019. Oncoinvent is pleased to announce it has appointed Tore Kvam as Chief Financial Officer. Mr. Kvam has a extensive experience as CFO with several years also within the life science industry. He holds an MBA from the Norwegian Business School, BI and is a Certified European Financial Analyst (CEFA) from the Norwegian School of Economics.

Read More »

New Radspherin® data published

Press Release 01.2018: Oncoinvent is pleased to announce today that Oncoinvent researchers have published data demonstrating the efficacy of the Radspherin® in two separate models of peritoneal carcinomatosis originating from ovarian cancer cell lines in the journal Translational Oncology.

Read More »

Radspherin® EU patent and OI-3 antibody US patent issued

Press Release: Oncoinvent announced today that European Patent 3111959 entitled ”Radiotherapeutic particles and suspensions” has issued. This patent provides patent protection for the company’s lead product candidate Radspherin® in Europe. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

Read More »

Oncoinvent presents Radspherin® preclinical data at 30th Annual Congress of the European Association of Nuclear Medicine (EANM)

Press Release 06.2017

Work presented indicates that, with certain precautions, 224Ra based biomedical products can be used in a safe manner for the hospital staff and patients.
In vivo studies show that 224Ra-labeled CaCO3 microparticles could be safely administered in mice at therapeutically relevant doses and with a high degree of intraperitoneal retention.
The novel α-emitting microparticles have properties that make them a promising new modality for intracavitary cancer therapy.

Read More »

Oncoinvent is on the move!

Oncoinvent announced today that will be moving operations from its current facilities at Kjelsåsveien 168B to a new location at Gullhaugveien 7 in Nydalen, Oslo in April. The move will provide the company with a larger office space as well as space for a new production and lab facililties.

Read More »

Oncoinvent patent issues in the USA

Press release: Oncoinvent announced today that US Patent 9,539,346 entitled “Radiotherapeutic particles and suspensions” has issued. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

Read More »

New Chief Executive Officer

The 1st of September 2016, Jan A. Alfheim entered the position as Chief Executive Officer (CEO) of Oncoinvent AS. Jan A. Alfheim comes from the position Chief Operation Officer (COO) in Nordic Nanovector ASA, where he until 2014 was responsible for the company’s leadership as CEO. Tina B. Bønsdorff enters the position as Chief Scientific

Read More »

15 million in a private placement

Oncoinvent AS has successfully completed a private placement. The share offering was directed towards Oncoinvent’s existing shareholders and a limited number of private investors. The issue was oversubscribed and will provide NOK 15 mill. to Oncoinvent, net of transaction costs.

Read More »

Oncoinvent awarded 4,6 MNOK in Innovation Funding

Press Release 04.2019: Oncoinvent is pleased to announce that the Oslo University Hospital and Oncoinvent have each been awarded Innovation Funding to develop Radspherin® as a treatment for colorectal cancer patients suffering from peritoneal carcinomatosis. The two awards make for a combined total of 7,9 million NOK where Oncoinvent will receive 4,6 MNOK and Oslo University Hospital 3,3 MNOK. The Innovation Norway grants will allow Oncoinvent to expand the clinical use of Radspherin® from the current planned study in ovarian cancer patients and enables the company to carry out phase 1 clinical trials to assess the clinical safety of Radspherin® in colorectal cancer patients as well.

Read More »

Oncoinvent announces appointment of new Chief Financial Officer

Press Release 02.2019. Oncoinvent is pleased to announce it has appointed Tore Kvam as Chief Financial Officer. Mr. Kvam has a extensive experience as CFO with several years also within the life science industry. He holds an MBA from the Norwegian Business School, BI and is a Certified European Financial Analyst (CEFA) from the Norwegian School of Economics.

Read More »

New Radspherin® data published

Press Release 01.2018: Oncoinvent is pleased to announce today that Oncoinvent researchers have published data demonstrating the efficacy of the Radspherin® in two separate models of peritoneal carcinomatosis originating from ovarian cancer cell lines in the journal Translational Oncology.

Read More »

Radspherin® EU patent and OI-3 antibody US patent issued

Press Release: Oncoinvent announced today that European Patent 3111959 entitled ”Radiotherapeutic particles and suspensions” has issued. This patent provides patent protection for the company’s lead product candidate Radspherin® in Europe. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

Read More »

Oncoinvent presents Radspherin® preclinical data at 30th Annual Congress of the European Association of Nuclear Medicine (EANM)

Press Release 06.2017

Work presented indicates that, with certain precautions, 224Ra based biomedical products can be used in a safe manner for the hospital staff and patients.
In vivo studies show that 224Ra-labeled CaCO3 microparticles could be safely administered in mice at therapeutically relevant doses and with a high degree of intraperitoneal retention.
The novel α-emitting microparticles have properties that make them a promising new modality for intracavitary cancer therapy.

Read More »

Oncoinvent is on the move!

Oncoinvent announced today that will be moving operations from its current facilities at Kjelsåsveien 168B to a new location at Gullhaugveien 7 in Nydalen, Oslo in April. The move will provide the company with a larger office space as well as space for a new production and lab facililties.

Read More »

Oncoinvent patent issues in the USA

Press release: Oncoinvent announced today that US Patent 9,539,346 entitled “Radiotherapeutic particles and suspensions” has issued. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

Read More »

New Chief Executive Officer

The 1st of September 2016, Jan A. Alfheim entered the position as Chief Executive Officer (CEO) of Oncoinvent AS. Jan A. Alfheim comes from the position Chief Operation Officer (COO) in Nordic Nanovector ASA, where he until 2014 was responsible for the company’s leadership as CEO. Tina B. Bønsdorff enters the position as Chief Scientific

Read More »

15 million in a private placement

Oncoinvent AS has successfully completed a private placement. The share offering was directed towards Oncoinvent’s existing shareholders and a limited number of private investors. The issue was oversubscribed and will provide NOK 15 mill. to Oncoinvent, net of transaction costs.

Read More »

Oncoinvent awarded 4,6 MNOK in Innovation Funding

Press Release 04.2019: Oncoinvent is pleased to announce that the Oslo University Hospital and Oncoinvent have each been awarded Innovation Funding to develop Radspherin® as a treatment for colorectal cancer patients suffering from peritoneal carcinomatosis. The two awards make for a combined total of 7,9 million NOK where Oncoinvent will receive 4,6 MNOK and Oslo University Hospital 3,3 MNOK. The Innovation Norway grants will allow Oncoinvent to expand the clinical use of Radspherin® from the current planned study in ovarian cancer patients and enables the company to carry out phase 1 clinical trials to assess the clinical safety of Radspherin® in colorectal cancer patients as well.

Read More »

Oncoinvent announces appointment of new Chief Financial Officer

Press Release 02.2019. Oncoinvent is pleased to announce it has appointed Tore Kvam as Chief Financial Officer. Mr. Kvam has a extensive experience as CFO with several years also within the life science industry. He holds an MBA from the Norwegian Business School, BI and is a Certified European Financial Analyst (CEFA) from the Norwegian School of Economics.

Read More »

New Radspherin® data published

Press Release 01.2018: Oncoinvent is pleased to announce today that Oncoinvent researchers have published data demonstrating the efficacy of the Radspherin® in two separate models of peritoneal carcinomatosis originating from ovarian cancer cell lines in the journal Translational Oncology.

Read More »

Radspherin® EU patent and OI-3 antibody US patent issued

Press Release: Oncoinvent announced today that European Patent 3111959 entitled ”Radiotherapeutic particles and suspensions” has issued. This patent provides patent protection for the company’s lead product candidate Radspherin® in Europe. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

Read More »

Oncoinvent presents Radspherin® preclinical data at 30th Annual Congress of the European Association of Nuclear Medicine (EANM)

Press Release 06.2017

Work presented indicates that, with certain precautions, 224Ra based biomedical products can be used in a safe manner for the hospital staff and patients.
In vivo studies show that 224Ra-labeled CaCO3 microparticles could be safely administered in mice at therapeutically relevant doses and with a high degree of intraperitoneal retention.
The novel α-emitting microparticles have properties that make them a promising new modality for intracavitary cancer therapy.

Read More »

Oncoinvent is on the move!

Oncoinvent announced today that will be moving operations from its current facilities at Kjelsåsveien 168B to a new location at Gullhaugveien 7 in Nydalen, Oslo in April. The move will provide the company with a larger office space as well as space for a new production and lab facililties.

Read More »

Oncoinvent patent issues in the USA

Press release: Oncoinvent announced today that US Patent 9,539,346 entitled “Radiotherapeutic particles and suspensions” has issued. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

Read More »

New Chief Executive Officer

The 1st of September 2016, Jan A. Alfheim entered the position as Chief Executive Officer (CEO) of Oncoinvent AS. Jan A. Alfheim comes from the position Chief Operation Officer (COO) in Nordic Nanovector ASA, where he until 2014 was responsible for the company’s leadership as CEO. Tina B. Bønsdorff enters the position as Chief Scientific

Read More »

15 million in a private placement

Oncoinvent AS has successfully completed a private placement. The share offering was directed towards Oncoinvent’s existing shareholders and a limited number of private investors. The issue was oversubscribed and will provide NOK 15 mill. to Oncoinvent, net of transaction costs.

Read More »

Jan Alan Alfheim

Chief Executive Officer

alfheim@oncoinvent.com

+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.